Figure 4.
Progression‐free survival (PFS) of all patients (a) and comparisons of survival according to Group A (EGFR mutation only in ctDNA) versus Group B (EGFR mutation in ctDNA and tumor DNA) (b); final dose of afatinib (c); and type of EGFR mutation (d). EGFRm, epidermal growth factor receptor mutation; ctDNA, circulating tumor DNA